IBDEI2I2 ; ; 04-FEB-2020
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,39916,1,4,0)
 ;;=4^A60.01
 ;;^UTILITY(U,$J,358.3,39916,2)
 ;;=^5000353
 ;;^UTILITY(U,$J,358.3,39917,0)
 ;;=B00.1^^152^2002^33
 ;;^UTILITY(U,$J,358.3,39917,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39917,1,3,0)
 ;;=3^Herpesviral Vesicular Dermatitis
 ;;^UTILITY(U,$J,358.3,39917,1,4,0)
 ;;=4^B00.1
 ;;^UTILITY(U,$J,358.3,39917,2)
 ;;=^5000468
 ;;^UTILITY(U,$J,358.3,39918,0)
 ;;=B97.89^^152^2002^89
 ;;^UTILITY(U,$J,358.3,39918,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39918,1,3,0)
 ;;=3^Viral Agent Cause of Disease
 ;;^UTILITY(U,$J,358.3,39918,1,4,0)
 ;;=4^B97.89
 ;;^UTILITY(U,$J,358.3,39918,2)
 ;;=^5000879
 ;;^UTILITY(U,$J,358.3,39919,0)
 ;;=B97.10^^152^2002^21
 ;;^UTILITY(U,$J,358.3,39919,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39919,1,3,0)
 ;;=3^Enterovirus Cause of Disease
 ;;^UTILITY(U,$J,358.3,39919,1,4,0)
 ;;=4^B97.10
 ;;^UTILITY(U,$J,358.3,39919,2)
 ;;=^5000861
 ;;^UTILITY(U,$J,358.3,39920,0)
 ;;=B34.9^^152^2002^90
 ;;^UTILITY(U,$J,358.3,39920,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39920,1,3,0)
 ;;=3^Viral Infection,Unspec
 ;;^UTILITY(U,$J,358.3,39920,1,4,0)
 ;;=4^B34.9
 ;;^UTILITY(U,$J,358.3,39920,2)
 ;;=^5000603
 ;;^UTILITY(U,$J,358.3,39921,0)
 ;;=A69.20^^152^2002^50
 ;;^UTILITY(U,$J,358.3,39921,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39921,1,3,0)
 ;;=3^Lyme Disease,Unspec
 ;;^UTILITY(U,$J,358.3,39921,1,4,0)
 ;;=4^A69.20
 ;;^UTILITY(U,$J,358.3,39921,2)
 ;;=^5000375
 ;;^UTILITY(U,$J,358.3,39922,0)
 ;;=A69.22^^152^2002^52
 ;;^UTILITY(U,$J,358.3,39922,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39922,1,3,0)
 ;;=3^Neurologic Disorders d/t Lyme Disease
 ;;^UTILITY(U,$J,358.3,39922,1,4,0)
 ;;=4^A69.22
 ;;^UTILITY(U,$J,358.3,39922,2)
 ;;=^5000377
 ;;^UTILITY(U,$J,358.3,39923,0)
 ;;=A69.21^^152^2002^51
 ;;^UTILITY(U,$J,358.3,39923,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39923,1,3,0)
 ;;=3^Meningitis d/t Lyme Disease
 ;;^UTILITY(U,$J,358.3,39923,1,4,0)
 ;;=4^A69.21
 ;;^UTILITY(U,$J,358.3,39923,2)
 ;;=^5000376
 ;;^UTILITY(U,$J,358.3,39924,0)
 ;;=A69.29^^152^2002^18
 ;;^UTILITY(U,$J,358.3,39924,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39924,1,3,0)
 ;;=3^Conditions d/t Lyme Disease
 ;;^UTILITY(U,$J,358.3,39924,1,4,0)
 ;;=4^A69.29
 ;;^UTILITY(U,$J,358.3,39924,2)
 ;;=^5000379
 ;;^UTILITY(U,$J,358.3,39925,0)
 ;;=A69.23^^152^2002^5
 ;;^UTILITY(U,$J,358.3,39925,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39925,1,3,0)
 ;;=3^Arthritis d/t Lyme Disease
 ;;^UTILITY(U,$J,358.3,39925,1,4,0)
 ;;=4^A69.23
 ;;^UTILITY(U,$J,358.3,39925,2)
 ;;=^5000378
 ;;^UTILITY(U,$J,358.3,39926,0)
 ;;=A51.0^^152^2002^29
 ;;^UTILITY(U,$J,358.3,39926,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39926,1,3,0)
 ;;=3^Genital Syphilis,Primary
 ;;^UTILITY(U,$J,358.3,39926,1,4,0)
 ;;=4^A51.0
 ;;^UTILITY(U,$J,358.3,39926,2)
 ;;=^5000272
 ;;^UTILITY(U,$J,358.3,39927,0)
 ;;=A52.3^^152^2002^54
 ;;^UTILITY(U,$J,358.3,39927,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39927,1,3,0)
 ;;=3^Neurosyphilis,Unspec
 ;;^UTILITY(U,$J,358.3,39927,1,4,0)
 ;;=4^A52.3
 ;;^UTILITY(U,$J,358.3,39927,2)
 ;;=^5000298
 ;;^UTILITY(U,$J,358.3,39928,0)
 ;;=A52.10^^152^2002^53
 ;;^UTILITY(U,$J,358.3,39928,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39928,1,3,0)
 ;;=3^Neurosyphilis Symptomatic,Unspec
 ;;^UTILITY(U,$J,358.3,39928,1,4,0)
 ;;=4^A52.10
 ;;^UTILITY(U,$J,358.3,39928,2)
 ;;=^5000291
 ;;^UTILITY(U,$J,358.3,39929,0)
 ;;=A52.9^^152^2002^49
